Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function?

Michael James Kraakman1,2, Andrew James Murphy2,3, Karin Jandeleit-Dahm4,5† and Hélène L. Kammoun1,†

1 Cellular and Molecular Metabolism Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia
2 Haematopoiesis and Leukocyte Biology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia
3 Department of Immunology, Monash University, Melbourne, VIC, Australia
4 Diabetic Complications Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia
5 Department of Medicine, Central Clinical School, Monash University, Melbourne, VIC, Australia

Obesity and type 2 diabetes are now recognized as chronic pro-inflammatory diseases. In the last decade, the role of the macrophage in particular has become increasingly implicated in their pathogenesis. Abundant literature now establishes that monocytes get recruited to peripheral tissues (i.e., pancreas, liver, and adipose tissue) to become resident macrophages and contribute to local inflammation, development of insulin resistance, or even pancreatic dysfunction. Furthermore, an accumulation of evidence has established an important role for macrophage polarization in the development of metabolic diseases. The general view in obesity is that there is an imbalance in the ratio of M1/M2 macrophages, with M1 “pro-inflammatory” macrophages being enhanced compared with M2 “anti-inflammatory” macrophages being down-regulated, leading to chronic inflammation and the propagation of metabolic dysfunction. However, there is emerging evidence revealing a more complex scenario with the spectrum of macrophage states exceeding well beyond the M1/M2 binary classification and confused further by human and animal models exhibiting different macrophage profiles. In this review, we will discuss the recent findings regarding macrophage polarization in obesity and type 2 diabetes.

Keywords: macrophage, inflammation, obesity, type 2 diabetes, M1/M2, polarization

Inflammation is a fundamental biological process whose role is not only to enable host protection against pathogens, but also to stimulate and modulate repair and healing when cellular damage occurs. During an inflammatory event, once the initial insult is contained, a primary objective is the restoration of tissue homeostasis. Failure to appropriately resolve an inflammatory stimulus can result in persistent immune system activation, which can actually cause tissue damage and disease. Significant literature over the last decades has established obesity to induce a state of chronic low-grade systemic inflammation (1). Importantly, the inflammation accompanying obesity is distinctly different to that of acute inflammation, as the inflammatory stimulus fails to be resolved. This is of particular significance as chronic low-grade inflammation is implicated in the etiology of atherosclerosis, hypertension, type 2 diabetes (T2D), and even certain cancers, which can all be associated with obesity (2, 3). Considering the economic burden from the increasing prevalence of these chronic metabolic diseases, it is not surprising that considerable scientific attention has focused on how and why obesity promotes chronic low-grade inflammation.

Immune cells are the primary effectors of most inflammatory reactions and are categorized into the innate and acquired immune systems. With respect to obesity, leukocytes from both immune systems have been implicated in the development of chronic low-grade inflammation and metabolic dysfunction (1). However, adipose tissue macrophages have received the lion’s share of attention of the immune cells involved. Macrophages can display remarkable phenotypic heterogeneity with the ability to perform vastly different roles depending on the biological situation (4). Thus, a spectrum of many different macrophage populations has been characterized by combinations of membrane markers and gene expression profiles. This led to the establishment of a complex nomenclature, which over time has become simplified into two main macrophage phenotypes, M1 pro-inflammatory and M2 anti-inflammatory macrophages. This classification is obviously a simplistic view of the situation as it is now clear that macrophages dynamically evolve from one phenotype to the other according to their environment and can occupy various points of the spectrum with mixed characteristics [for updated nomenclature see Ref. (5, 6)]. For clarity purposes, we will mostly mention macrophages as either M1 or M2.

MACROPHAGE ACCUMULATION IN THE OBESE ADIPOSE TISSUE

Phagocytosis is a main function of macrophages that allows them to contribute to tissue homeostasis through surveillance,
White adipose tissue macrophage accumulation is thought to occur through two main processes. First, increased chemokine secretion from adipocytes and resident macrophages promotes the recruitment of Ly6C<sup>+</sup> blood monocytes to obese WAT. Most of these monocytes subsequently differentiate into M1 macrophages in response to inflammatory signals within the adipose tissue. Of the chemokines produced from obese WAT, monocyte chemoattractant protein-1 (MCP-1) and its receptor C–C motif receptor-2 (CCR2) appear particularly important. For example, mice lacking either CCR2 or MCP-1 have reduced ATMs, whereas adipocyte specific over-expression of MCP-1 leads to enhanced ATMs (20, 21). However, these knockout models did not normalize macrophage numbers suggesting additional mechanisms are likely to be involved in obesity-induced macrophage accumulation (20). Indeed, obese WAT secretes many chemokines including LTβ4, MIP, MIF, and MCP-3 implicated in macrophage accumulation and glucose intolerance (22). Interestingly, in addition to chemokine secretion, signals from obese WAT also influence bone marrow progenitor cells to increase myelopoiesis. Indeed, we have recently demonstrated that in obese mice, IL1β production from CD11c<sup>+</sup> ATMs promoted bone marrow myelopoiesis further perpetuating adipose tissue inflammation (23). Second, resident ATMs have a strong proliferation capacity in both human beings and rodents. Indeed, Jenkins et al. showed that IL4 is a strong promoter of macrophage proliferation (24). Hence, in the lean state where eosinophils secrete high levels of IL4 in the WAT, proliferation is considered the major mechanism to maintain resident M2 macrophage populations (24–26). Interestingly, Amano et al. revealed that MCP-1 could enhance macrophage proliferation in the visceral WAT independent of its chemokine function (27). It is clear that further studies are required to determine the contribution of macrophage proliferation and recruitment to adipose tissue macrophage accumulation in obesity.

MACROPHAGE FATE

While the recruitment and source of macrophages present in obese adipose tissue are well documented, the fate of these recruited macrophages in obesity is thought to occur through two main processes. First, increased chemokine secretion from adipocytes and resident macrophages promotes the recruitment of Ly6C<sup>+</sup> blood monocytes to obese WAT. Most of these monocytes subsequently differentiate into M1 macrophages in response to inflammatory signals within the adipose tissue. Of the chemokines produced from obese WAT, monocyte chemoattractant protein-1 (MCP-1) and its receptor C–C motif receptor-2 (CCR2) appear particularly important. For example, mice lacking either CCR2 or MCP-1 have reduced ATMs, whereas adipocyte specific over-expression of MCP-1 leads to enhanced ATMs (20, 21). However, these knockout models did not normalize macrophage numbers suggesting additional mechanisms are likely to be involved in obesity-induced macrophage accumulation (20). Indeed, obese WAT secretes many chemokines including LTβ4, MIP, MIF, and MCP-3 implicated in macrophage accumulation and glucose intolerance (22). Interestingly, in addition to chemokine secretion, signals from obese WAT also influence bone marrow progenitor cells to increase myelopoiesis. Indeed, we have recently demonstrated that in obese mice, IL1β production from CD11c<sup>+</sup> ATMs promoted bone marrow myelopoiesis further perpetuating adipose tissue inflammation (23). Second, resident ATMs have a strong proliferation capacity in both human beings and rodents. Indeed, Jenkins et al. showed that IL4 is a strong promoter of macrophage proliferation (24). Hence, in the lean state where eosinophils secrete high levels of IL4 in the WAT, proliferation is considered the major mechanism to maintain resident M2 macrophage populations (24–26). Interestingly, Amano et al. revealed that MCP-1 could enhance macrophage proliferation in the visceral WAT independent of its chemokine function (27). It is clear that further studies are required to determine the contribution of macrophage proliferation and recruitment to adipose tissue macrophage accumulation in obesity.

MACROPHAGE FATE

While the recruitment and source of macrophages present in obese adipose tissue are well documented, the fate of these recruited macrophages in obesity is thought to occur through two main processes. First, increased chemokine secretion from adipocytes and resident macrophages promotes the recruitment of Ly6C<sup>+</sup> blood monocytes to obese WAT. Most of these monocytes subsequently differentiate into M1 macrophages in response to inflammatory signals within the adipose tissue. Of the chemokines produced from obese WAT, monocyte chemoattractant protein-1 (MCP-1) and its receptor C–C motif receptor-2 (CCR2) appear particularly important. For example, mice lacking either CCR2 or MCP-1 have reduced ATMs, whereas adipocyte specific over-expression of MCP-1 leads to enhanced ATMs (20, 21). However, these knockout models did not normalize macrophage numbers suggesting additional mechanisms are likely to be involved in obesity-induced macrophage accumulation (20). Indeed, obese WAT secretes many chemokines including LTβ4, MIP, MIF, and MCP-3 implicated in macrophage accumulation and glucose intolerance (22). Interestingly, in addition to chemokine secretion, signals from obese WAT also influence bone marrow progenitor cells to increase myelopoiesis. Indeed, we have recently demonstrated that in obese mice, IL1β production from CD11c<sup>+</sup> ATMs promoted bone marrow myelopoiesis further perpetuating adipose tissue inflammation (23). Second, resident ATMs have a strong proliferation capacity in both human beings and rodents. Indeed, Jenkins et al. showed that IL4 is a strong promoter of macrophage proliferation (24). Hence, in the lean state where eosinophils secrete high levels of IL4 in the WAT, proliferation is considered the major mechanism to maintain resident M2 macrophage populations (24–26). Interestingly, Amano et al. revealed that MCP-1 could enhance macrophage proliferation in the visceral WAT independent of its chemokine function (27). It is clear that further studies are required to determine the contribution of macrophage proliferation and recruitment to adipose tissue macrophage accumulation in obesity.
macrophages remains less studied. Unlike resolving inflammation in which levels of inflammatory leukocytes subside following the restoration of tissue homeostasis, adipose tissue inflammation induced by excessive adiposity fails to resolve naturally. During resolving inflammation, it is well appreciated that the initially recruited polymorphonuclear neutrophils undergo swift apoptosis prompting their phagocytosis by macrophages. Despite early evidence for macrophage emigration and drainage to lymph nodes as a significant contributor to macrophage disappearance following acute inflammation, recent work from the Randolph laboratory has revealed that macrophage apoptosis is largely responsible for their removal in acute inflammation (28). Whether these mechanisms contribute to adipose tissue macrophage accumulation in non-resolving inflammation is not well studied. For example, whether M1 macrophages accumulate within obese adipose tissue due to pro-survival/anti-apoptotic signals remains unknown. However, it is also possible that macrophages are actively retained within the adipose tissue in response to various cues. Netrin-1, best described for its role in neural development, has recently been implicated in macrophage retention within obese adipose tissue (29). However, these findings are somewhat at odds with the plethora of studies showing the importance of monocyte/macrophage recruitment, repopulation (e.g., after bone marrow transplantation), and proliferation to the macrophage burden in the obese adipose tissue and perhaps plays only a minor role.

A MORE COMPLEX PICTURE THAN M1 OR M2

Macrophages are able to modify their phenotype according to their environment. However, whether macrophage phenotype switching occurs in obesity remains unresolved (30, 31). Shaul et al. demonstrated that in HFD-fed animals' classical M1 macrophage accumulation is observed after 8 weeks of diet, however, after 12 weeks of diet, these CD11c+ macrophages exhibited an increased expression of M2 associated transcripts (32). While the M1 macrophages maintained their pro-inflammatory phenotype, they also adopted some remodeling features in a context of increased adipogenesis reminiscent of M2. Conversely, M2 macrophages are able to secrete pro-inflammatory mediators in specific conditions (33). These studies reveal extremely dynamic macrophage populations and newer technologies such as live imaging undoubtedly will enhance our understanding of the changes occurring in macrophage polarization state upon weight gain. Indeed, Haase et al. showed recently that most adipose tissue macrophages arising in situ stained positive for the M2 markers CD206 and CD301 (34). Live imaging and tracking techniques allowed the revelation that newly formed M2 macrophages originate within the CLS before they migrate to the interstitial space. Given that CLS form around dying adipocytes, the presence of M2 macrophages could be viewed as a resolving mechanism. Given that macrophages are able to alter their phenotype and that most studies assess adipose tissue macrophage content at one single time, care must be exercised when interpreting data. For example, one cannot expect to predict a metabolic phenotype based upon observed adipose tissue macrophage polarity.

It remains plausible that the inflammation associated with obesity initially constitutes a physiological rather than pathological process within the adipose tissue. Indeed, in an elegant study, Scherer and colleagues have demonstrated that adipocyte inflammation is essential for adipose tissue expansion and remodeling (35). Using the "adipocytometer," they tracked newly formed adipocytes and distinguished them from older "blue" adipocytes expressing β-galactosidase. They determined that acute inflammation promotes adipogenesis and improved adipose tissue function and insulin sensitivity. Conversely, they demonstrated that abrogation of inflammation within the adipose tissue led to defective adipogenesis followed by ectopic lipid accumulation and glucose intolerance (35). These findings highlight a previously unappreciated role for inflammation per se in healthy adipose tissue function.

CAN WE TARGET IMMUNITY TO TREAT T2D?

It is important to ensure that the findings made in rodent models are useful in human pathology. It is clear that macrophages also accumulate in adipose tissue of obese humans (7) and have been correlated with insulin resistance (36). Wentworth et al. also showed that pro-inflammatory CD11c+ macrophages are positively associated with systemic insulin resistance in obese patients (37). Furthermore, macrophage content is reduced in the adipose tissue following gastric bypass surgery (38). Importantly, in these patients, the macrophage status was switched toward a less pro-inflammatory profile. However, other groups have shown that the accrued macrophages in human adipose tissue present M2 surface markers associated with a more anti-inflammatory phenotype (39, 40). Nonetheless, Zeyda et al. showed that these M2 macrophages possess a strong capacity to produce pro-inflammatory mediators (39). These discrepancies may be explained by different experimental protocols. In most studies, WAT is obtained from subcutaneous depots whereas fewer studies report data obtained from omental WAT. Furthermore, the sex and degree of adiposity of the patients may also account for some of the differences reported. The same reasons may partly explain the inconsistencies observed between mice and human beings. In addition, important metabolic differences between rodents and human beings contribute to the difficulty of translating mouse data into human therapies.

In addition, there are further evidences that inflammation and macrophages should be targeted with the greatest care in T2D. Indeed, Chawla's group recently reported that M2 macrophages can secrete catecholamines in response to cold exposure, activating thermogenesis of brown adipose tissue and lipolysis of WAT (41). They later found that M2 macrophages were directly involved in the "beginning" of adipose tissue (42). In addition, a current article proposed that M2 macrophages strongly promote β-cell proliferation (43). The presented studies tend to suggest that the positive effects of macrophages in obesity and T2D are carried on by repair macrophages exhibiting an M2 phenotype. Hence, there appears to be a rationale targeting the enhancement of M2 populations as opposed to depleting M1 macrophages, which may jeopardize the patient's immune function. However, increased M2 macrophage function is also tightly linked to tumor proliferation.
so manipulating M2 populations must be considered carefully as obese patients already present with an increased incidence of cancer (2).

CONCLUSION
It is increasingly appreciated that immune cells play a crucial role in the control of whole body metabolism (2). In light of this view, it seems clear that the macrophage accumulation within the adipose tissue is associated with metabolic dysfunction observed in obesity. However, the role of macrophages in the pathogenesis of obesity and diabetes is still conflicting. In addition to the complexity of the immune response itself, different rodent models, the use of different high-fat diets and of different intervention time courses not to add the different environments of each animal facility, have often led to contradictory results raising more confusion within the field. As it was nicely exposed in a recent review by Murray et al., it is important for the coherence of results in this domain that researchers try and decide which models to focus on to allow the field to progress and result in more human translational potential (5).

In this review, we have summarized the recent findings on the role of macrophages in obesity and T2D. M1 macrophage accumulation within the adipose tissue remains tightly associated with obesity. It is still unclear how much this accumulation contributes to the glucose intolerance and insulin resistance described in obese rodent models. There is growing literature suggesting their presence could be required for physiological adaptations of the adipose tissue (35). Perhaps these findings reflect the dynamic nature of macrophage polarity and the essential role of macrophages in the biology of adipose tissue (Figure 1). However, it is also important to take a “non-glucose/insulin resistant-centric view” with respect to the role of adipose tissue macrophages and to appreciate that they could also contribute significantly to the risk of other associated diseases including cardiovascular disease and cancer. As a whole, these data advocate that macrophages should be targeted with the greatest care in metabolic diseases.

REFERENCES
1. Kammoun HL, Kraakman MJ, Febbraio MA. Adipose tissue inflammation in glucose metabolism. Rev Endocr Metab Disord (2014) 15(1):31–44. doi:10.1007/s11154-013-9274-4
2. Noto H, Goto A, Tsujimoto T, Osame K, Noda M. Latest insights into the risk of cancer in diabetes. J Diabetes Investig (2013) 4(3):225–32. doi:10.1111/jdi.12068
3. Osborn O, Olefsky JM. The cellular and signalling networks linking the immune system and metabolism in disease. Nat Med (2012) 18(3):363–74. doi:10.1038/nm.2627

4. Okabe Y, Medzhov R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell (2014) 157(4):832–44. doi:10.1016/j.cell.2014.04.016

5. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 41(1):14–20. doi:10.1016/j.immuni.2014.06.008

6. Guilliams M, Ghinhoux F,Jakubzick C, Naik SH, Onai N, Schraml BU, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontology. Nat Rev Immunol (2014) 14(8):571–8. doi:10.1038/nri.2014.72

7. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 112(12):1796–808. doi:10.1172/JCI19246

8. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest (2003) 112(12):1821–30. doi:10.1172/JCI19451

9. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (1993) 259(5099):87–91. doi:10.1126/science.7678183

10. Desvergne B. PPARdelta/beta: the lobbyist switching macrophage allegiance. Immunity (2014) 41(1):1–4. doi:10.1016/j.immuni.2013.04.004

11. Amano SU, Cohen JL, Vangala P, Tenczerova M, Nicoloro SM, Yaw JC, et al. Local proliferation of macrophages contributes to obesity-associated adipose tissue inflammation. Cell Metab (2014) 19(4):162–71. doi:10.1016/j.cmet.2013.11.017

12. Repoila G. Mechanisms that regulate macrophage burden in atherosclerosis. Circ Res (2011) 114(1):1755–71. doi:10.1161/CIRCRESAHA.114.3110174

13. Gunjewar V, Noble NK, Thompson K, Vaid A, Burdge GC. Adipose tissue macrophages in morbid obesity: influence of glycemic status. J Clin Invest (2009) 120(6):2660–2. doi:10.1172/JCI36352

14. Wang ZV, et al. Adipocyte inflammation is essential for healthy adipose tissue that normally change their functional phenotype in response to changes in microenvironmental influences. J Immunol (2005) 175(1):342–9. doi:10.4049/jimmunol.175.1.342

15. Li P, Lu M, Nguyen MT, Rae EJ, Chapman J, Feng D, et al. Functional heterogeneity of CD11c+apositive adipose tissue macrophages in diet-induced obese mice. J Biol Chem (2010) 285(20):15335–45. doi:10.1074/jbc.M110.016263

16. Hae se J, Weyer U, Immig K, Kloting N, Bluher M, Eilers J, et al. Local proliferative of macrophages in adipose tissue during obesity-induced inflammation. Diabetologia (2014) 57(5):562–71. doi:10.1007/s00125-013-3119-9

17. Wentworth JM, Girgis YM, Ruckerl D, Jenkins S, Ward LN, Kurtz GD, et al. Altered proportion of obesity-associated increases in CD11c+ adipose tissue macrophages that normally change their functional phenotype in response to changes in microenvironmental influences. Diabetes (2010) 59(5):1171–81. doi:10.2337/db10-069

18. Naya M, Matsui Y, Haneda M, Muro K, Hojo A, Usui T, et al. Adipose tissue macrophages promote myelopoiesis and monocyte recruitment in obesity. Cell Metab (2014) 19(5):821–35. doi:10.1016/j.cmet.2014.03.029

19. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelstein FD, van Rooijen N, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science (2011) 332(6055):1284–8. doi:10.1126/science.1204351

20. Weisberg SP, Hunter D, Huber R, Lesniak J, Slaymaker S, Vaddi K, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science (2011) 332(6062):243–7. doi:10.1126/science.1204175

21. Kraakman et al. Macrophage polarization in metabolic diseases.

22. Surmi BK, Hasty AH. The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue. Vascul Pharmacol (2010) 52(1–2):27–36. doi:10.1016/j.vph.2009.12.004
41. Nguyen KD, Qiu Y, Cai X, Goh YP, Mwangi J, David T, et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. *Nature* (2011) **480**(7375):104–8. doi:10.1038/nature10653

42. Qiu Y, Nguyen KD, Odegard JI, Cai X, Tian X, Lockley RM, et al. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. *Cell* (2014) **157**(6):1292–308. doi:10.1016/j.cell.2014.03.066

43. Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, et al. M2 macrophages promote beta-cell proliferation by up-regulation of SMAD7. *Proc Natl Acad Sci U S A* (2014) **111**(13):E1211–20. doi:10.1073/pnas.1321347111

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 21 August 2014; accepted: 12 September 2014; published online: 26 September 2014.

Citation: Kraakman MJ, Murphy AJ, Jandeleit-Dahm K and Kammoun HL (2014) Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function? *Front. Immunol.* 5:470. doi: 10.3389/fimmu.2014.00470

This article was submitted to Molecular Innate Immunity, a section of the journal *Frontiers in Immunology*.

Copyright © 2014 Kraakman, Murphy, Jandeleit-Dahm and Kammoun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.